$4.81
-0.01-0.21%
After Hours: 4:00 PM EDT
Comments
Loading...
Vanda Pharmaceuticals Stock Guidance | NASDAQ:VNDA | Benzinga
Vanda Pharmaceuticals issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/13/2025 | VNDA | Vanda Pharma | FY | 2030 | ā | ā | ā | $1.00B | ā | ā | Get Alert |
| 02/13/2025 | VNDA | Vanda Pharma | FY | 2025 | ā | ā | ā | $210.00M | $250.00M | $284.90M | Get Alert |
| 11/06/2024 | VNDA | Vanda Pharma | FY | 2024 | ā | ā | ā | $190.00M | $210.00M | $198.33M | Get Alert |
| 07/31/2024 | VNDA | Vanda Pharma | FY | 2024 | ā | ā | ā | $180.00M | $210.00M | $207.34M | Get Alert |
| 11/02/2022 | VNDA | Vanda Pharma | FY | 2022 | ā | ā | ā | $240.00M | $270.00M | $273.80M | Get Alert |
| 08/03/2022 | VNDA | Vanda Pharma | FY | 2022 | ā | ā | ā | $240.00M | $280.00M | $265.10M | Get Alert |
| 05/05/2022 | VNDA | Vanda Pharma | FY | 2022 | ā | ā | ā | $240.00M | $280.00M | $265.10M | Get Alert |
| 02/23/2022 | VNDA | Vanda Pharma | FY | 2022 | ā | ā | ā | $240.00M | $280.00M | $313.62M | Get Alert |
| 11/03/2021 | VNDA | Vanda Pharmaceuticals | FY | 2021 | ā | ā | ā | $260.00M | $290.00M | $283.71M | Get Alert |
| 07/28/2021 | VNDA | Vanda Pharmaceuticals | FY | 2021 | ā | ā | ā | $270.00M | $300.00M | $282.92M | Get Alert |
| 05/05/2021 | VNDA | Vanda Pharmaceuticals | FY | 2021 | ā | ā | ā | $270.00M | $300.00M | $283.40M | Get Alert |
| 02/10/2021 | VNDA | Vanda Pharmaceuticals | FY | 2021 | ā | ā | ā | $270.00M | $300.00M | $279.40M | Get Alert |
| 10/28/2020 | VNDA | Vanda Pharma | FY | 2020 | ā | ā | ā | $240.00M | $260.00M | $251.05M | Get Alert |
| 08/05/2020 | VNDA | Vanda Pharma | FY | 2020 | ā | ā | ā | $240.00M | $260.00M | $249.40M | Get Alert |
FAQ
What is the most recent guidance for Vanda Pharmaceuticals (VNDA)?
There have been no specific sales or earnings guidance reported for Vanda Pharmaceuticals in recent months.
Browse guidance and forecast on all stocks.